DPP-4 inhibitors for treating T2DM - hype or hope? an analysis based on the current literature

Frontiers in Molecular Biosciences

Molecular Biosciences

Yousuf Khan¹  Kunika Saini¹  Smriti Sharma² 

[1] Molecular Modelling and Drug Design Laboratory, Department of Chemistry, University of Delhi, New Delhi, India;null;

关键词: T2DM;    incretin effect;    DPP-4 enzyme;    DPP-4 inhibitors;    (GLP)-1;    insulin;   

DOI  :  10.3389/fmolb.2023.1130625

 received in 2022-12-28, accepted in 2023-05-08,  发布年份 2023

来源: Frontiers

【 摘 要 】

DPP-4 inhibition is an interesting line of therapy for treating Type 2 Diabetes Mellitus (T2DM) and is based on promoting the incretin effect. Here, the authors have presented a brief appraisal of DPP-4 inhibitors, their modes of action, and the clinical efficiency of currently available drugs based on DPP-4 inhibitors. The safety profiles as well as future directions including their potential application in improving COVID-19 patient outcomes have also been discussed in detail. This review also highlights the existing queries and evidence gaps in DPP-4 inhibitor research. Authors have concluded that the excitement surrounding DPP-4 inhibitors is justified because in addition to controlling blood glucose level, they are good at managing risk factors associated with diabetes.

【 授权许可】

Unknown   
Copyright © 2023 Saini, Sharma and Khan.